RecruitingPhase 2NCT06690697

Combination of Toripalimab and JS004 Therapy for ccRCC

Studying Clear cell renal carcinoma

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fudan University
Intervention: JS004(drug)
Enrollment: 80 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2026

Study locations (1)

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06690697 on ClinicalTrials.gov

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT07128680
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
RECRUITINGPHASE2NCT06863311
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Karie Runcie
RECRUITINGPHASE2NCT07397611
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
RECRUITINGPHASE2NCT07469683
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
RECRUITINGPHASE2NCT07188896
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Brian Rini
RECRUITINGPHASE1, PHASE2NCT07227415
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
RECRUITINGPHASE1, PHASE2NCT07551349
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Beijing Biotech
RECRUITINGPHASE2NCT07223541
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
University of Oklahoma

See all trials for Clear cell renal carcinoma →

← Back to all trials